The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.

Ola Myklebost
Ola Myklebost

Norwegian Cancer Genomics Consortium (NCGC) consists of clinicians and specialised cancer research groups, situated at the Norwegian University Hospitals, and is led by professor Ola Myklebost (photo) from the Department of Tumor Biology at Oslo University Hospital.
The NCGC participates in an international study of gene variants predisposing for cancer development. Findings from the study has recently been published in Lancet Oncology (journal impact factor 24.69). The article - entitled "Monogenic and polygenic determinants of sarcoma risk: an international genetic study" has also got an editorial comment: "Are sarcomas hereditary?".

Ny blogg Eva W Straford debuterer med blogg om Sarkomprosjektet

Vil behandle sjeldne kreftformer med personlig medisinering
Det finnes ingen nye medisiner utviklet spesielt mot den sjeldne kreftformen sarkom. En forskningsgruppe ved Radiumhospitalet, Oslo universitetssykehus, jobber nå for å finne en måte å behandle denne ondartede kreftformen på gjennom å lese genkoden til alle sarkomer som opereres i Norge over en treårsperiode. Et stort og viktig prosjekt, skriver postdoktor Eva Wessel Stratford denne uken i bloggen Forskningssykehuset.
>> Les bloggen på

Chronicle on personalised cancer medicine in Aftenposten

Illustration photo: Aftenposten
Illustration photo: Aftenposten

Norway's largest newspaper Aftenposten recently printed a chronicle on personalized cancer medicine, entitled "Should every cancer patient become their own research project"? Here, leader of the National Cancer Genomics Consortium, professor Ola Myklebost, and colleagues professors Per Eystein Lønning, Bjørn Tore Gjertsen and Ragnhild A. Lothe point out that in "personalized medicine", cancer patients remain the largest and increasing group that may benefit most from new treatment strategies.
The authors emphasize the importance of increase in national clinical trials and participation in high quality international studies for the benefit of the Norwegian cancer patient and to strengthen the Norwegian professional development and research.

På sporet av årsaker til kreft Foredrag og paneldebatt på Stavanger kunstmuseum

Som en del av Article Biennalen 2015 på MUST - Stavanger Kunstmuseum, holdt Ola Myklebost foredrag og paneldebatt om persontilpasset kreftbehandling. I panelet satt også Bjørnar Gilje, Onkolog, Emiel Janssen, molekylærbiolog, og Oddmund Nordgård, molekylærbiolog, alle fra Stavanger Universitetssykehus.

Meza-Zepeda and Myklebost co-author recent Cancer Cell publication on the architecture and evolution of cancer neochromosomes

Meza-Zepeda (left) and Myklebost
Meza-Zepeda (left) and Myklebost

Leonardo A. Meza-Zepeda and Ola Myklebost in collaboration with David M. Thomas’ group in Australia co-author an article recently published in Cancer Cell (journal impact factor 23.89), entitled “The Architecture and Evolution of Cancer Neochromosomes”.
This article describes for the first time, at single base resolution, the architecture of cancer-associated neochromosomes in well- and dedifferentiated liposarcomas.

Oslo University Hospital has award 6 excellent articles for the first half-year of 2014

Bjrn Erikstein, managing director OUS

Oslo University Hospital has rewarded six research groups for their excellent papers published during the first half-year of 2014. Each group receives NOK 50.000 for use in further research. The prizes were distributed during the Friday meeting at Ullevål November 21st.
The award winners gave short presentations of the main findings in their respective articles. Managing director Bjørn Erikstein (photo) distributed the awards, and professor Ole M. Sejerstad chaired the meeting.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

Helse Sørøst Månedens forsker januar 2013 Genomknekkeren

Månedens forsker januar 2013:


Ola Myklebost jakter på formelen for persontilpasset kreftbehandling. Først må han knekke kreftgenomet.
Av Ram Gupta, Oslo universitetssykehus , Helse Sør-Øst RHF
Bilde av Ola Myklebost 
Ola Myklebost er månedens forsker i Helse Sør-Øst.

Ved hjelp av avansert genteknologi presser de på for å knekke koden til kreftgenomet, Ola Myklebost og hans forskerkolleger.

Når koden gir etter kan de finne formelen for persontilpasset kreftbehandling.

Basert på en analyse av mutasjonsprofilen til den enkelte kreftsvulsten ønsker de å fastsette en perfekt miks av individuelt tilpassede medisiner. Pasienten slipper å gå på flere kreftmedisiner enn nødvendig.

Kreftbehandlingen kan bli billigere for samfunnet og mer skånsom for pasienten.

Les oppslaget

OUS-led national personalised cancer medicine project granted generously by BIOTEK 2021.

The BIOTEK2021 programme is the Research Council of Norway’s most comprehensive research initiative in the field of biotechnology and will run from 2012 through 2021. The programme board has now granted support to five large projects, covering all relevant thematic fields, and are expected to boost the development of commercial biotechnology in Norway.
One of the carefully selected projects is entitled "A national research and innovation platform for personalized cancer medicine", and is led by Ola Myklebost (photo) from the Department of Tumor Biology at OUS.

Substantial support from "The Programme for Publicly-initiated Clinical Cancer Studies" to projects led by Mælandsmo, Loge and Myklebost

Tumor Biology scientists celebrating
Tumor Biology scientists celebrating

The Programme for Publicly-initiated Clinical Cancer Studies provides support to research projects that will increase understanding and thereby enhance the basis for effective decision-making within cancer treatment and care. The Research Council collaborates with the Norwegian Council for Quality Improvement and Priority Setting in Health Care on the selection of proposed topics for calls for proposals.

The program has recently decided to distribute a sum amounting to about 65 mill NOK among three projects, all of which are led by scientists from the Norwegian Radium Hospital, OUS: Gunhild Mælandsmo, Jon Håvard Loge and Ola Myklebost. This was celebrated on Friday April 13th (photo from the celebration under "More").

News article in Nature on Norwegian plans for using tumour-sequencing techniques to help guide cancer care

O. Myklebost
O. Myklebost

The February 2nd edition of Nature brings a feature article in their news section about Norway's current plans to use "next-generation" DNA sequencers to trawl for mutations in tumours that might reveal which cancer treatments would be most effective.
Ola Myklebost (photo), senior researcher at the Department of Tumor Biology and leader of The Norwegian Cancer Genomics Consortium, who is spearheading the effort, is interviewed for the article, which is entitled "Norway to bring cancer-gene tests to the clinic".

Findings from Ola Myklebost's group published in Cancer

Myklebost and Kresse
Myklebost and Kresse
As members of the European Network of Excellence Eurobonet, the group of Ola Myklebost has assembled and characterised in detail a large collection of preclinical models of sarcoma, malignant tumours of connective tissue. In a recent study published in Cancer, the journal of the American Cancer Society, with Stine Kresse and Ola Myklebost (photo) as first and last author - they used array-based comparative genomic hybridisation (arrayCGH) employing in-house arrays to compare in great detail to what extent a panel of sarcoma xenografts - human tumour samples propagated by serial transplantation in immune-deficient mice - are identical to their tumour of origin, and whether there are systematic changes that occur during passaging in mice.

Two first class MScs from our group Tale and Eivind complete their MSC exams with As


Tale Barøy


Characterization of LSAMP, a novel candidate tumor suppressor gene in osteosarcomas.

Veileder Ola Myklebost, Leonardo Meza-Zepeda, Stine H. Kresse

Sensor: Heidi Rudi, UMB, Uwe Klein, IMBV


Evaluation: A


Eivind Valen Egeland

Osteogenic differentiation of mesenchymal stem cells:  Identification of potential regulators

Veileder Ola Myklebost, Leonardo Meza-Zapeda, Anne Mari Håkelien

Sensorer: Heidi Rudi, UMB, Paul E. Grini, IMBV

Evaluation: A




International Sarcoma Symposium Radiumhospitalet, Oslo

Supported by the Liddy Shriver Sarcoma Initiative, we have established an international liposarcoma research consortium, consisting of two American (MakiBarretina), one Australian (Thomas), and one Norwegian group (Myklebost/Meza-Zepeda). This web site is set up to further this collaboration and invite other groups to provide their links, as well as to advertise what we are doing in the hope to extend our collaborations further.

The ILPC is having its inaugural workshop in Oslo Feb 3-6 2011, which opens up with an open symposium at the Norwegian Radium Hospital.